These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 9048364)
21. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET. Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312 [TBL] [Abstract][Full Text] [Related]
22. Toward a statistically relevant calibration end point for prostate seed implants. Rosenzweig DP; Schell MC; Yu Y Med Phys; 2000 Jan; 27(1):144-50. PubMed ID: 10659750 [TBL] [Abstract][Full Text] [Related]
23. The effect of seed orientation deviations on the quality of 125I prostate implants. Corbett JF; Jezioranski JJ; Crook J; Tran T; Yeung IW Phys Med Biol; 2001 Nov; 46(11):2785-800. PubMed ID: 11720347 [TBL] [Abstract][Full Text] [Related]
24. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. Beaulieu L; Archambault L; Aubin S; Oral E; Taschereau R; Pouliot J Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1298-308. PubMed ID: 15001275 [TBL] [Abstract][Full Text] [Related]
25. Examining the relationship between pre- and postimplant geometry in prostate low-dose-rate brachytherapy and its correlation with dosimetric quality using the similarity concept. Todor DA; Anscher MS; Karlin JD; Hagan MP Brachytherapy; 2014; 13(5):471-80. PubMed ID: 25037911 [TBL] [Abstract][Full Text] [Related]
26. Optimization of permanent 125I prostate implants using fast simulated annealing. Pouliot J; Tremblay D; Roy J; Filice S Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):711-20. PubMed ID: 8948357 [TBL] [Abstract][Full Text] [Related]
27. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability. D'Souza WD; Thames HD; Kuban DA Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335 [TBL] [Abstract][Full Text] [Related]
28. Modification of prostate implants based on postimplant treatment margin assessment. Mueller A; Wallner K; Merrick G; Courveau J; Sutlief S; Butler W; Gong L; Cho P Med Phys; 2002 Dec; 29(12):2782-7. PubMed ID: 12512711 [TBL] [Abstract][Full Text] [Related]
29. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom. Lesperance M; Martinov M; Thomson RM Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710 [TBL] [Abstract][Full Text] [Related]
30. Effect of random seed placement error in permanent transperineal prostate seed implant. Bues M; Holupka EJ; Meskell P; Kaplan ID Radiother Oncol; 2006 Apr; 79(1):70-4. PubMed ID: 16515813 [TBL] [Abstract][Full Text] [Related]
31. Two-dimensional dose distribution of 125I seeds. Ling CC; Schell MC; Yorke ED; Palos BB; Kubiatowicz DO Med Phys; 1985; 12(5):652-5. PubMed ID: 4047002 [TBL] [Abstract][Full Text] [Related]
32. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer. Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077 [TBL] [Abstract][Full Text] [Related]
33. Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Edmundson GK; Yan D; Martinez AA Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1257-63. PubMed ID: 7493850 [TBL] [Abstract][Full Text] [Related]
34. The use of anisotropic data in 125I prostate implants. Fox RA; Haworth A; Mina LL Australas Phys Eng Sci Med; 1997 Jun; 20(2):57-63. PubMed ID: 9262024 [TBL] [Abstract][Full Text] [Related]
35. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose. Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195 [TBL] [Abstract][Full Text] [Related]
36. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry. Dicker AP; Lin CC; Leeper DB; Waterman FM Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458 [TBL] [Abstract][Full Text] [Related]
37. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution. Todor DA; Barani IJ; Lin PS; Anscher MS Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392 [TBL] [Abstract][Full Text] [Related]
38. Improved treatment planning for COMS eye plaques. Astrahan MA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905 [TBL] [Abstract][Full Text] [Related]
39. Prostate brachytherapy: comparison of dose distribution with different 125I source designs. Beyer DC; Puente F; Rogers KL; Gurgoze EM Radiology; 2001 Dec; 221(3):623-7. PubMed ID: 11719655 [TBL] [Abstract][Full Text] [Related]